Compare XOMA & FTHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XOMA | FTHY |
|---|---|---|
| Founded | 1981 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 457.6M | 539.8M |
| IPO Year | N/A | N/A |
| Metric | XOMA | FTHY |
|---|---|---|
| Price | $32.23 | $14.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $69.50 | N/A |
| AVG Volume (30 Days) | 53.6K | ★ 176.7K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.93% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $47,106,000.00 | N/A |
| Revenue This Year | $88.91 | N/A |
| Revenue Next Year | $13.80 | N/A |
| P/E Ratio | $39.11 | ★ N/A |
| Revenue Growth | ★ 118.02 | N/A |
| 52 Week Low | $18.35 | $12.66 |
| 52 Week High | $39.92 | $14.74 |
| Indicator | XOMA | FTHY |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 58.03 |
| Support Level | $31.18 | $13.82 |
| Resistance Level | $32.78 | $14.21 |
| Average True Range (ATR) | 1.53 | 0.11 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 24.73 | 95.24 |
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.